Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00944-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Waki Imoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Levofloxacin, Cephalosporins, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation, Morinomiyako Medical Research Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cefiderocol (CFDC) is a promising drug for treating infections caused by Stenotrophomonas maltophilia , a multidrug-resistant pathogen. However, no evidence of its efficacy against S. maltophilia -induced hemorrhagic pneumonia has been reported. We compared the effects of CFDC and levofloxacin (LVFX) on improving survival as well as reducing bacterial load and pathological effects in a mouse model of S. maltophilia hemorrhagic pneumonia. The dosage of LVFX and CFDC was determined using a previously described method to establish S. maltophilia- induced hemorrhagic pneumonia in mice. CFDC and LVFX were administered intraperitoneally 3 h after bacterial infection. Treatment was administered using the calculated dosages. CFDC significantly improved survival, showed a tendency to reduce bacterial load in the blood and lungs, and revealed that hemorrhage was suppressed in pathological analysis compared with the control group. These results support the current recommendation for CFDC as a treatment option for S. maltophilia infections. However, its efficacy in our model was lower than that of LVFX. This may be due to the superior pulmonary tissue penetration of LVFX. Treatment strategies that consider tissue penetration are necessary for severe S. maltophilia infections. However, the use of LVFX must consider the risk of resistance development, whereas CFDC may be advantageous for treating resistant pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Infectious Disease Medicine, Osaka Metropolitan University Hospital, Osaka, Japan.
- Department of Infection Control and Prevention, Osaka Metropolitan University Hospital, Osaka, Japan.
- Research Center for Infectious Disease Sciences (RCIDS), Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Osaka International Research Center for Infectious Diseases (OIRCID), Osaka Metropolitan University, Osaka, Japan.
- Department of Bacteriology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Waki Imoto
Förderung
- Takeda Science Foundation
- Morinomiyako Medical Research Foundation
- Japan Society for the Promotion of Science
- Japanese Society for Chemotherapy 70th Anniversary Research Support Program
Zitieren
APA
Imoto, W., Abe, J., Sakurai, N., Kawamoto, K., Yamada, K., Kaneko, Y., & Kakeya, H. (2026). Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00944-25
Vancouver
Imoto W, Abe J, Sakurai N, Kawamoto K, Yamada K, Kaneko Y, et al. Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00944-25
BibTeX
@article{Imoto2026,
author = {Imoto, Waki and Abe, Junko and Sakurai, Norihiro and Kawamoto, Kengo and Yamada, Koichi and Kaneko, Yukihiro and Kakeya, Hiroshi},
title = {Efficacy of cefiderocol and levofloxacin against Stenotrophomonas maltophilia in a hemorrhagic pneumonia mouse model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00944-25}
}
EUVIMED